Global gene therapy market to reach $300 million by 2015

The global gene therapy market is expected to grow to over $300 million by 2015, according to a new report available on companiesandmarkets.com. The gene therapy market will grow further driven by the human genome project, the increasing incidence of cancer and other critical diseases.

Gene Therapy: A Global Strategic Business Report

Gene therapy has seen success in the treatment of diseases such as myelination disorder X-linked ALD (adenoleukodystrophy), ADA-SCID (adenosine deaminase deficiency-related severe combined immunodeficiency), and Leber congenital amaurosis in discrete trials.

Gendicine was the first gene therapy to be approved in China for treating squamous cell carcinoma in January 2004. Also known as Recombinant Ad-p53 Anti-cancer Injection, Gendicine was developed by Shenzhen SiBiono Gene Technologies Co. (SiBiono) Ltd. Globally, there are five drugs awaiting clearance from relevant regulatory authorities, including HGF DNA Plasmid from Sosei and Daiichi Sankyo which is a proposed treatment for peripheral vascular disease. In addition, Collategene and Glybera are the latest drugs being assessed by regulatory authorities in Japan and Europe respectively. Gendicine and Rexin-G are the only gene therapies receiving approval which are marketed in China and Philippines, respectively.

The gene therapy industry is dominated by Oncology, Infectious diseases, and genetic disorders applications. However, therapeutic applications of gene therapy are extending to new therapy areas such as acquired diseases. In addition, smaller companies are likely to become more visible in future as their products move closer to regulatory approvals.

The majority of companies in gene therapy are working on therapies targeting multifactoral conditions and cancer is the key targeted condition of gene therapy projects globally. Companies profiled in the gene therapy research report include AnGes MG Inc., BioSante Pharmaceuticals, GenVec, Genzyme Corporation, Oxford BioMedica, Shenzhen SiBiono GeneTech Co., Ltd, Transgene, Urigen Pharmaceuticals Inc., and Vical, Inc.

Source:

 companiesandmarkets.com

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
New discovery may open the door to targeted treatments for two types of rhabdomyosarcoma